#Glucagon-like peptide-1 analogs market

[versatile-blogger-1]

Global Glucagon-Like Peptide-1 Analogs Market Is Estimated To Witness High Growth Owing To Increasing Demand For Diabetes Treatment

A) Market Overview Glucagon-Like Peptide-1 (GLP-1) analogs are a class of medications primarily used in the treatment of type 2 diabetes. They mimic the effects of GLP-1, a hormone that helps regulate blood sugar levels. GLP-1 analogs work by stimulating insulin secretion, slowing down gastric emptying, and suppressing appetite. The key advantage of these analogs is their ability to lower blood sugar levels without causing hypoglycemia. With the rising prevalence of diabetes worldwide, there is a growing demand for effective treatment options, driving the growth of the GLP-1 analogs market.

The global Glucagon-Like Peptide-1 Analogs Market Size is estimated to be valued at US$ 11.87 billion in 2023, with a projected Compound Annual Growth Rate (CAGR) of 1.12% from 2023 to 2028. B) Market Key Trends One key trend in the Glucagon-Like Peptide-1 (GLP-1) Analogs market is the increasing adoption of long-acting GLP-1 analogs. These medications have a prolonged duration of action, allowing for once-weekly dosing instead of daily injections. This offers convenience for patients and improves treatment adherence. For example, Novo Nordisk's semaglutide and Eli Lilly's dulaglutide are long-acting GLP-1 analogs that have gained popularity due to their efficacy and ease of use. C) PEST Analysis Political: Government regulations and policies regarding the approval and pricing of GLP-1 analogs can impact market growth. For example, changes in reimbursement policies can affect the affordability and accessibility of these medications. Economic: The increasing healthcare expenditure and the rising prevalence of diabetes contribute to the growth of the GLP-1 analogs market. Additionally, the availability of generic versions of these medications at lower prices can influence market dynamics. Social: Growing awareness about diabetes management and the importance of maintaining blood sugar control is driving the demand for GLP-1 analogs. Lifestyle changes and sedentary lifestyles are leading to an alarming increase in diabetes cases worldwide. Technological: Advances in drug delivery systems, such as the development of pen injectors and continuous glucose monitoring devices, enhance the ease of administration and monitoring of GLP-1 analogs. D) Key Takeaways In terms of market size, the global GLP-1 analogs market is expected to witness high growth, exhibiting a CAGR of 1.12% over the forecast period. This growth is attributed to the increasing demand for diabetes treatment, driven by factors such as rising prevalence of diabetes and growing awareness about its management. In terms of regional analysis, North America is the fastest-growing and dominating region in the GLP-1 analogs market. The region has a high prevalence of diabetes and well-established healthcare infrastructure. Europe is also a significant market for GLP-1 analogs, with several key players based in the region. Key players operating in the global GLP-1 analogs market include Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca plc, GlaxoSmithKline plc F., and Hoffmann-La Roche Ltd. These companies focus on research and development activities to introduce innovative GLP-1 analogs and strengthen their market presence. In conclusion, the global Glucagon-Like Peptide-1 (GLP-1) Analogs market is expected to experience substantial growth due to the increasing demand for diabetes treatment. The adoption of long-acting GLP-1 analogs and technological advancements in drug delivery systems further contribute to market growth. However, government regulations and pricing policies can impact the market dynamics. North America and Europe are the key regions driving market growth, while key players in the market continue to focus on innovation and expansion strategies.

[cmibloggers]

In recent years, a breakthrough in diabetes management has emerged in the form of Glucagon-Like Peptide-1 (GLP-1) analogs. These innovative medications have revolutionized the treatment landscape by providing improved glycemic control and additional benefits for individuals with type 2 diabetes. 

Read More: https://cmibloggers.blogspot.com/2023/06/understanding-glucagon-like-peptide-1.html

[peptide-ltd]

CagriSema, Cagrilintide&Semaglutide, new peptide in Phcoker 2024!

Novo Nordisk “Cagrilintide/semaglutide” Research

Cagrilintide and Semaglutide overview

Cagrilintide: As a non-selective agonist for both amylin receptor (AMYR) and alcitonin G protein-coupled receptor (CTR), it confidently reduces food intake, resulting in significant weight loss. Cagrilintide peptide is an exciting amylin analog that has shown strong potential in the study of obesity. Cagrilintide is currently being tested alone and in combination with Semaglutide for the treatment of obesity and type 2 diabetes.

Semaglutide: Semaglutide is an amazing peptide belonging to the class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs)! This medication is truly a game-changer! It expertly mimics the GLP-1 hormone, significantly increases insulin release, effectively lowers glucagon release, expertly delays gastric emptying, and greatly reduces appetite.

Cagrilintide/semaglutide: A fixed dose combination of Cagrilintide and Semaglutide is under development for the treatment of type 2 diabetes, obesity and metabolic dysfunction-associated steatohepatitis (MASH). It administered through subcutaneous route. Cagrilintide is a long-acting amylin analogue which acts by targeting calcitonin receptor, receptor activity modifying proteins 1, 2, 3 (RAMP 1-3) and semaglutide acts by targeting glucagon like peptide 1 receptor (GLP1R).

Novo Nordisk overview

Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases, and obesity.

Cagrilintide/semaglutide Researches

【REDEFINE 2】A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

Brief Summary: This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance. It will last for about 1.5 years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

Official Title: Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes

【REDEFINE 3】A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Brief Summary: This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called “placebo”) which has no effect on the body. Which treatment participants will get will be decided by chance. Participant’s chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years.

Official Title: The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

The review of CagriSema’s researches provides a comprehensive understanding of its background, effects, and development direction. CagriSema powder is an emerging weight-loss peptide in the market, and only a few manufacturers have mastered its production technology. For research purposes, we recommend purchasing from Phcoker, which offers GMP pharmaceutical-grade quality to meet your needs and provide reliable answers to your questions.

What Is CagriSema Peptide? Is it Cagrilintide?

CagriSema peptide, the combination of Cagrilintide and Semaglutide, indeed presents a promising approach in the treatment of both obesity and type 2 diabetes. The synergy between these two medications seems to offer greater therapeutic benefits than either drug alone, as evidenced by the preliminary trial results showing significant weight loss and improved glycemic control.

Individuals seeking weight management often opt for Semaglutide due to its efficacy, and the potential of CagriSema to deliver even more powerful results is understandably appealing. The Phase II trial results, demonstrating a substantial average weight loss of -15.6% after 32 weeks, reinforce the potential of CagriSema as a formidable option in weight management.

The upcoming head-to-head trial comparing CagriSema to Tirzepatide will provide crucial insights into their comparative efficacy and safety profiles, aiding clinicians in making informed treatment decisions for their patients. The continued advancement of CagriSema into Phase III trials underscores its potential to address the complex challenges posed by type 2 diabetes and obesity.

Overall, CagriSema represents an exciting development in the field of metabolic disorders, offering hope for improved outcomes and better quality of life for individuals struggling with these conditions.

CagriSema Ttherapy

The progression of Cagrilintide and Semaglutide combination therapy (CagriSema) into Phase III for type 2 diabetes represents a significant milestone in its clinical development. With Novo Nordisk spearheading this effort, the focus is on evaluating its efficacy and safety in a larger population of patients.

The Phase III stage is pivotal, as it provides further insights into the drug’s effectiveness, potential side effects, and overall risk-benefit profile. The fact that it has advanced to this stage indicates promising results from earlier phases and underscores the interest in its therapeutic potential.

GlobalData’s benchmark of a 52% phase transition success rate (PTSR) for Phase III drugs in type 2 diabetes highlights the challenges associated with advancing treatments in this field. However, it’s important to note that each drug and clinical trial is unique, and success rates can vary based on various factors such as the mechanism of action, study design, patient population, and safety profile.

As CagriSema progresses through Phase III trials, its performance will be closely monitored, with the ultimate goal of demonstrating its efficacy and safety to regulators and healthcare providers. If it meets the desired endpoints and safety criteria, it could potentially advance to pre-registration, bringing us closer to offering a new treatment option for individuals living with type 2 diabetes.

What Benefits Can You Get From CagriSema?

CagriSema holds promise as a comprehensive treatment option for individuals with type 2 diabetes and obesity, offering a combination of glycemic control, weight loss, appetite regulation, and potential cardiovascular benefits.

CagriSema for Managing Type 2 Diabetes

CagriSema, a combination of Cagrilintide and Semaglutide, is a promising treatment for type 2 diabetes. The individual efficacy of Cagrilintide and Semaglutide in improving glycemic control and aiding weight loss makes the combination therapy an intriguing prospect for managing type 2 diabetes.

Ongoing clinical trials, including Phase II and Phase III studies, are evaluating the safety and efficacy of CagriSema specifically in patients with type 2 diabetes. Early results from these trials confidently indicate that CagriSema can provide greater benefits for weight loss and glycemic control compared to either medication alone.

The diplomatic dual mechanism of action, which combines the effects of a GLP-1 agonist (Semaglutide) with a dual amylin and calcitonin receptor agonist (Cagrilintide), may lead to synergistic effects, resulting in improved outcomes for patients with type 2 diabetes.

As more research is conducted and additional data becomes available, clinicians will gain a better understanding of the potential role of CagriSema in managing type 2 diabetes. If proven to be both effective and safe, CagriSema could be a valuable addition to the current treatments available for this complex metabolic disorder.

Cagrisema for Weight Loss

CagriSema peptide is a highly promising treatment for weight loss, particularly in individuals with obesity or overweight conditions. The two components of CagriSema, Cagrilintide and Semaglutide, work through different mechanisms of action to effectively reduce body weight.

Cagrilintide, a dual amylin and calcitonin receptor agonist, regulates appetite and food intake by acting on the central nervous system. Semaglutide, a GLP-1 receptor agonist, reduces food consumption and induces satiety, leading to decreased calorie intake. It mimics the action of the natural hormone GLP-1, which is released in response to food intake and promotes feelings of fullness, thereby reducing appetite and calorie consumption. This medication has been shown to be effective in clinical trials and is a promising option for those looking to manage their weight.

CagriSema powder is a highly effective weight loss treatment that combines Cagrilintide and Semaglutide. The results of early clinical trials and research have been very promising, with participants experiencing significant reductions in body weight when treated with CagriSema.

By combining two medications with complementary mechanisms of action, it offers a promising approach to weight loss. CagriSema in Phcoker has the potential to be a novel and valuable treatment option for managing obesity and overweight conditions. As more data become available and research progresses, CagriSema is likely to become an increasingly important tool in the fight against obesity.

Cagrisema for Cancer Treatment

Cagrisema (omacetaxine mepesuccinate) is a prescription medication used to treat chronic myeloid leukemia (CML). It is a type of chemotherapy drug that works by targeting certain proteins on the cancer cells, which helps to stop the growth of the cancer cells. Cagrisema is typically administered as an injection under the skin and must be taken daily for up to 18 months.

It is important to note that while CagriSema is still undergoing clinical development, it has shown promising results in weight management. However, further research is needed to fully understand its efficacy, safety, and long-term effects. As with any medication, it may not be suitable for everyone and should be used under the guidance of a healthcare professional. Phcoker is a trustworthy peptide supplier, with sales staff providing online guidance and providing the best quotations and logistics.

[lalsingh228-blog]

Anti-diabetic Medication Market is Set To Fly High in Years to Come

Global Anti-diabetic Medication Market Report from AMA Research highlights deep analysis on market characteristics, sizing, estimates and growth by segmentation, regional breakdowns & country along with competitive landscape, player’s market shares, and strategies that are key in the market. The exploration provides a 360° view and insights, highlighting major outcomes of the industry. These insights help the business decision-makers to formulate better business plans and make informed decisions to improved profitability. In addition, the study helps venture or private players in understanding the companies in more detail to make better informed decisions. Major Players in This Report Include, AstraZeneca plc (United Kingdom), Bayer AG (Germany), C.H. Boehringer Sohn AG & Ko. KG (Germany), Bristol-Myers Squibb (United States), Eli Lilly (United States), Halozyme Therapeutics (United States), Johnson & Johnson (United States), Merck & Co. Inc. (United States), Novartis AG (Switzerland), Pfizer Inc. (United States). Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/162818-global-anti-diabetic-medication-market Anti-diabetic medications are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Anti-diabetic medications are commonly used to manage diabetes. Anti-diabetic medications are all pharmacological agents that have been approved for hyperglycemic treatment in diabetes mellitus. The increasing prevalence of diabetes across the globe will stimulate the market potential for anti-diabetic medication during the forecast period. Market Drivers

Rising Prevalence of Chronic Diseases like Diabetes across the Globe

Growing Prevalence of Lifestyle-Induced Disorders such as Obesity

Market Trend

Increasing Adoption of Oral Antidiabetic Drugs

Opportunities

Rising Spending on Research and Development for Innovative Drugs

Challenges

Safety Issues Pertaining to Some Diabetic Drugs

Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/162818-global-anti-diabetic-medication-market In this research study, the prime factors that are impelling the growth of the Global Anti-diabetic Medication market report have been studied thoroughly in a bid to estimate the overall value and the size of this market by the end of the forecast period. The impact of the driving forces, limitations, challenges, and opportunities has been examined extensively. The key trends that manage the interest of the customers have also been interpreted accurately for the benefit of the readers. The Anti-diabetic Medication market study is being classified by Type (Insulin (Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin), Drug class (Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione)), Application (Prevent and Treatment Diabetes, Obesity Treatment, Cardiovascular Protection, Others), Route of Administration (Insulin Syringe/ Insulin Pen, Insulin Pump, Intravenous Infusion, Oral, Others), End User (Pediatric, Adult, Geriatric) The report concludes with in-depth details on the business operations and financial structure of leading vendors in the Global Anti-diabetic Medication market report, Overview of Key trends in the past and present are in reports that are reported to be beneficial for companies looking for venture businesses in this market. Information about the various marketing channels and well-known distributors in this market was also provided here. This study serves as a rich guide for established players and new players in this market. Get Reasonable Discount on This Premium Report @ https://www.advancemarketanalytics.com/request-discount/162818-global-anti-diabetic-medication-market Extracts from Table of Contents Anti-diabetic Medication Market Research Report Chapter 1 Anti-diabetic Medication Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition by Manufacturers Chapter 4 Global Revenue (Value, Volume*) by Region Chapter 5 Global Supplies (Production), Consumption, Export, Import by Regions Chapter 6 Global Revenue (Value, Volume*), Price* Trend by Type Chapter 7 Global Market Analysis by Application ………………….continued This report also analyzes the regulatory framework of the Global Markets Anti-diabetic Medication Market Report to inform stakeholders about the various norms, regulations, this can have an impact. It also collects in-depth information from the detailed primary and secondary research techniques analyzed using the most efficient analysis tools. Based on the statistics gained from this systematic study, market research provides estimates for market participants and readers. Contact US : Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 201 565 3262, +44 161 818 8166 sales@advancemarketanalytics.com

[shradhacmi]

Global Semaglutide Market Is Estimated To Witness High Growth Owing To Novo Nordisk A/S and Eli Lilly and Company

The global semaglutide market is estimated to be valued at USD 2.17 billion in 2021 and is expected to exhibit a CAGR of 8.71% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. A) Market Overview: Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that is used for the treatment of diabetes. It helps to lower blood sugar levels by increasing insulin production and reducing glucose production in the liver. Semaglutide is administered through injection and is available in both once-daily and once-weekly formulations. It has shown promising results in clinical trials and is being widely used as a second-line therapy for type 2 diabetes. B) Market Dynamics: The market for semaglutide is being driven by two key drivers: the increasing prevalence of diabetes and the growing demand for effective treatment options. 1. Increasing prevalence of diabetes: The global prevalence of diabetes is on the rise, mainly due to sedentary lifestyles, unhealthy dietary habits, and an aging population. According to the International Diabetes Federation, the number of people with diabetes is expected to reach 700 million by 2045. This growing patient pool is fueling the demand for better diabetes management options, including semaglutide. 2. Growing demand for effective treatment options: Semaglutide offers several advantages over traditional oral antidiabetic medications, such as better glycemic control, weight loss, and cardiovascular benefits. These benefits have resulted in increased adoption of semaglutide as a preferred treatment option by healthcare professionals and patients alike. Furthermore, the introduction of once-weekly formulations has improved patient compliance and convenience, further driving market growth. C) SWOT Analysis: Strength: 1. Efficacy in glycemic control 2. Cardiovascular benefits Weakness: 1. Injection-based administration 2. Higher cost compared to oral antidiabetic medications Opportunity: 1. Rising adoption in emerging markets 2. Potential application in obesity management Threats: 1. Competition from other GLP-1 analogs 2. Stringent regulatory requirements D) Key Takeaways: - The global Semaglutide Market is expected to witness high growth, exhibiting a CAGR of 8.71% over the forecast period. The increasing prevalence of diabetes and the growing demand for effective treatment options are the key drivers contributing to this growth. - Regionally, North America is expected to dominate the semaglutide market due to the high prevalence of diabetes in the region and the early adoption of novel therapies. However, the Asia-Pacific region is expected to witness the fastest growth, primarily driven by the large diabetic population and increasing healthcare expenditure. - Key players operating in the global semaglutide market include Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca PLC, Sanofi S.A., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Johnson & Johnson, Bristol-Myers Squibb Company, AbbVie Inc., Pfizer Inc., Mylan N.V., Novartis International AG, Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Ltd. In conclusion, the global semaglutide market is poised for significant growth in the coming years, driven by the increasing prevalence of diabetes and the demand for effective treatment options. The market offers opportunities for key players to capitalize on the rising adoption of semaglutide, both in established and emerging markets. However, competition and regulatory requirements remain potential challenges in this dynamic market.

[blogomonaco]

Global Glucagon Like Peptide 1 Analogs Market Is Estimated To Witness High Growth

The global Glucagon Like Peptide 1 Analogs Market is estimated to be valued at US$ 12.55 billion in 2021 and is expected to exhibit a CAGR of 6.10% over the forecast period of 2022 to 2029, according to a new report published by Coherent Market Insights.

A) Market Overview:

Glucagon-Like Peptide-1 (Glp-1) Analogs are a class of medications used for the management of type 2 diabetes. They mimic the action of the Glp-1 hormone in the body, which helps regulate blood sugar levels. These drugs are administered through injections and have been proven effective in controlling blood glucose, reducing weight, and decreasing the risk of cardiovascular events. The growing prevalence of diabetes worldwide and the expanding geriatric population are driving the demand for Glp-1 Analogs, resulting in market growth.

B) Market Dynamics:

The market dynamics for Glucagon-Like Peptide-1 (Glp-1) Analogs can be attributed to two main drivers. Firstly, the increasing prevalence of diabetes globally is a major driver for market growth. The World Health Organization (WHO) estimates that the number of people with diabetes will reach 552 million by 2030. Glp-1 Analogs provide an effective treatment option for managing diabetes, leading to their high demand in the market.

Secondly, the expanding geriatric population is another driver for the Glp-1 Analogs market. The elderly population is more prone to developing diabetes, and with the growing aging population, the demand for diabetes management medications is increasing. Glp-1 Analogs offer a targeted and efficient approach to controlling blood sugar levels in the elderly, making them a preferred choice among healthcare professionals.

C) Segment Analysis:

The Glucagon Like Peptide 1 Analogs Market can be segmented based on drug type, distribution channel, and region. By drug type, the market can be divided into Exenatide, Liraglutide, Dulaglutide, and others. Liraglutide is expected to dominate the market due to its high efficacy and preference among healthcare providers. By distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies are anticipated to be the dominant segment due to the availability of a wide range of Glp-1 Analogs in these settings.

D) PEST Analysis:

Political: Government initiatives to control the prevalence of diabetes by implementing strict regulations for pharmaceutical companies can impact the growth of the Glp-1 Analogs market.

Economic: The increasing healthcare expenditure and the rising affordability of Glp-1 Analogs in developing countries contribute to market growth.

Social: Changing lifestyles, unhealthy eating habits, and sedentary lifestyles are major social factors leading to the rise in diabetes cases globally.

Technological: Advancements in drug delivery systems and the development of innovative Glp-1 Analogs formulations are driving the market growth.

E) Key Takeaways:

The global Glucagon Like Peptide 1 Analogs Market is expected to witness high growth, exhibiting a CAGR of 6.10% over the forecast period.

The increasing prevalence of diabetes and the expanding geriatric population are the major drivers for market growth.

Liraglutide is expected to dominate the market due to its high efficacy and preference among healthcare providers.

Hospital pharmacies are anticipated to be the dominant distribution channel for Glp-1 Analogs.

Key players operating in the global Glucagon Like Peptide 1 Analogs Market include Sun Pharmaceuticals Industries Ltd, Bristol-Myers Squibb Company, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc, Baxter, Amneal Pharmaceuticals, LLC, Hikma Pharmaceuticals plc, Teva Pharmaceuticals Industries Ltd, Mylan N.V, and Fresenius K.

[takingcareofoneself]

Glucagon-like peptide-1 (GLP-1) analogues, also known as incretin mimetics, are a type of diabetic medication used to lower blood sugar levels in people with type 2 diabetes. GLP-1 analogues block GLP-1 breakdown, increasing glucose-dependent insulin release, suppressing glucagon release (lowering hepatic glucose output), and slowing gastric emptying (resulting in weight loss from reduced appetite). GLP-1 analogues, unlike other anti-diabetic medicines, do not produce hypoglycemia. In addition, GLP-1 analogues help people lose weight.

High prevalence of diabetes in the U.S. and Asia-Pacific is expected to drive the growth of Glucagon-like peptide-1 analogs market

[martynnx-blog]

Glucagon-Like Peptide-1 (Glp-1) Analogs Market Evolving Industry Trends and Key Insights by 2026

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic medications. Also, GLP-1 analogs provide weight reduction benefit.

Download PDF Brochure Of This Research Report @https://www.coherentmarketinsights.com/insight/request-pdf/1252

High prevalence of diabetes in the U.S. and Asia-Pacific is expected to drive the growth of Glucagon-like peptide-1 analogs market:

According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, around 425 million patients are suffering from diabetes worldwide. According to World Health Organization (WHO) report 2017, diabetes is one of top three cause of death among the non-communicable diseases. China (114.4 million), India (72.9 million) and U.S. (30.2 million) are top three economies having high prevalence of diabetes. Such high number of prevalence would offers an immense growth opportunity to the GLP-1 analogs market. This is also from the fact that approximately 212.4 million people worldwide are with undiagnosed diabetes. According to the International Diabetes Federation (IDF), the U.S. has highest prevalence of diabetes (13% of population), which is expected to drive the growth of glucagon-like peptide-1 analogs market, owing to cost effectiveness and high penetration of these product in market. GLP-1 analogs not only act in type-2 diabetes but also in type 1 diabetes with almost nil hypoglycemic effect, according to the study published in the Journal of American Health and Drug Benefit. According to study published in journal Obesity Review (2017), GLP-1 analogs aid in weight reduction of diabetic as well as non-diabetic obese patient. GLP-1 analog liraglutide is already approved in treating obese and overweight patient, which is expected to fuel the growth of the GLP-1 analogs market.

Increasing awareness amongst physicians regarding benefits of GLP-1 analogs over conventional anti-diabetic medication is propelling the growth of the market.

GLP-1 analogs are administered through subcutaneous injection with the help of injectable pen, which are relatively expensive (US$ 492 for 30-day therapy) as compared to conventional type-2 diabetes medication such as insulin sensitizers and secretagogues (US$ 5-9 for 30-day therapy) which is the major factor restraining growth of the market. Also, there is an issue of patient compliance. For instance, GLP-1 analogs need to be administered through injection as compared to other anti-diabetic medications, which are taken orally in tablet form.

Inquire Here Before Purchase of Research Report @https://www.coherentmarketinsights.com/insight/talk-to-analyst/1252

Glucagon-Like Peptide-1 Analogs Market Taxonomy:

On the basis of drug:

Exenatide

Liraglutide

Lixisenatide

Dulaglutide

Semaglutide

Albiglutide

On the basis of distribution channel:

Retail Pharmacy

Hospital pharmacy

Exenatide is the first GLP-1 analog approved in 2005, marketed by AstraZeneca under brand names Byetta and Byedureon Bcise. Its patent expired in October 2017. Teva got approval to commercialize the generic version of Byetta and its abbreviated new drug application is under FDA review. Novo Nordisk in October 2017 received FDA approval for once-a-week GLP-1 analog semaglutide. GSK announced to discontinue the global sale of albiglutide brand Tanzeum, Eperzan from July 2018 due to low profits. Taspoglutide is a molecule being developed by Roche targeting once a week dosing as against daily dosing regimen of other GLP-1 analogs. However, in 2016 it decided to halt clinical development due to high gastrointestinal side effects and hypersensitivity reactions.

Key players operating in the global Glucagon-like peptide-1 analogs market include Novo Nordisk, Eli-Lilly and Company, Sanofi, AstraZeneca plc, GlaxoSmithKline plc F., Hoffmann-La Roche Ltd.

[healthcaredbmrnews]

Diagnostic imaging equipment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to grow at a CAGR of 5.90% in the above-mentioned forecast period.

[databridgemarres]

Data Bridge market research analyzed that the Diagnostic Imaging Devices Market will show a CAGR of around 5.72% for the forecast period 2021-2028. Increased public spending on advances in diagnostic imaging equipment, increased focus on R&D capabilities in medical devices and adoption of advanced healthcare technologies, and rising costs for healthcare infrastructure development, particularly in emerging markets, are the key factors driving the diagnostic imaging equipment market.

[shreyas-inkwood]

Product Innovation Compel Funding in the Global Diabetes Drugs Market

One of the key factors augmenting the risk of developing diabetes and prediabetes is age. A visible rise in the geriatric population has been witnessed globally over several decades, and this trend is estimated to be constant in the future, as well. Hence, the average life expectancy, coupled with the prevailing incidences of diabetes, majorly influence the global diabetes drugs market. While the leading risk is type 2 diabetes, a large pool of recently diagnosed diabetics constitutes the elderly age group.

Below highlighted are the key statistical facts to the most recent data:

As per the International Diabetes Federation (IDF), the number of people with diabetes worldwide reached 425 million in 2017 and is further expected to reach 629 million by 2045.

According to the estimations issued by the IDF in 2017, approximately 1.1 million children and adolescents across the globe have Type 1 diabetes.

The United States Centers for Disease Control and Prevention (CDC) National Diabetes Report Statistics 2017 states that 30.3 million Americans had diabetes in 2015, representing one in 10 of the country’s total population. Also, in the same year, an estimated 1.5 million new cases of diabetes were diagnosed among United States adults aged 18 years or older.

In Europe, the population of people aged 80 and above is projected to double between 2013 and 2040.

Since numerous physiological alterations are witnessed within older aged patients, the disease’s classic symptoms may not be expected to manifest. Besides, changes due to age can mask those indications. However, important factors leading to Type 1 and Type 2 diabetes include:

Increased thirst

Unexplained weight loss

Fatigue

Irritability

Recurrent infections, such as gum, skin, and vaginal infections

Blurred vision

Frequent urination

Slow-healing sores

The treatment and diagnosis of diabetes among older adults demands increased flexibility and a customized approach. Moreover, owing to the population’s heterogeneity varying in terms of life expectancy, the need to control blood glucose concomitant of chronic diseases as well as the intake of injections increases. Older adults with long-term diabetes, coupled with several other chronic complications, require a liberal methodology to counter specific goals in terms of the treatment.

The elderly populace diagnosed with diabetes are highly susceptible to chronic complications such as dementia and Alzheimer’s disease, cardiovascular disorders (CVDs), frailty syndrome, damage to the eyes, kidney failure, and foot ulcers. Therefore, during the course of the treatment, it is essential to consider the side effects of the medications and drug interactions.

The most common drugs applicable for treating Type 2 diabetes in the older age group are:

Sulphonylureas – Sulphonylureas is an oral medication that helps control sugar levels in the patient’s blood with Type 2 diabetes. It stimulates insulin production in the pancreas and enhances the efficacy of insulin in the body.

Metformin – Categorized within the biguanideclass, it is an antihyperglycemic agent used for the treatment of Type 2 diabetes. Currently, it is the choicest drug adopted for the management of the condition and is prescribed worldwide.

Glucagon – Like peptide-1 analogs, the drug is shown to assist other treatments in the management of Type 2 diabetes. Usually, they are prescribed once on a daily basis (liraglutide) or twice by subcutaneous injection.

Gliptins – As the first agent of sitagliptin, it was approved by the FDA in 2006. They are majorly utilized in treating diabetes mellitus Type 2 by blocking the enzyme dipeptidyl peptidase-4 (DPP-4).

Flozins – The sodium-glucose transport protein 2 inhibitor is a type 2 diabetes medication that reabsorbs glucose in the kidney and lowers the blood sugar level.

Thiazolidinediones – Also referred to as glitazones, Thiazolidinediones are a group of oral anti-diabetic drugs prescribed as a remedy for Type 2 diabetes.

Insulin – Insulin therapy is a medication used in both Types 1 and 2 diabetes. Insulin helps regulate sugar levels in the blood and also stores excess glucose for energy.

To Conclude

Top manufacturers in the global diabetes drug market, such as Sanofi, Novo Nordisk A/S, AstraZeneca, Merck, and Eli Lilly and Company, are heavily investing in developing a pipeline of innovative drugs to discourse the unmet needs of patients. The market interprets investment activities as a capacity expansion plan with rigorous research and development (R&D) aimed at obtaining maximum growth opportunities over the upcoming years. This factor will further intensify the competition with a direct positive effect on the advent of new drugs, product extensions, as well as novel applications of products and services.

[jesse-pinkman123]

Peptide-Based Gastrointestinal Disorders Therapeutics Market Analysis-2027

Peptide-Based Gastrointestinal Disorders Therapeutics Market Regional Analysis

North America Peptide-Based Gastrointestinal Disorders Therapeutics Market is expected to exhibit good growth over the forecast period, owing to presence of major players and adoption of strategies such as mergers and collaborations by them for novel peptide-based therapeutics. For instance, in February 2018, Cipher Pharmaceuticals Inc. acquired exclusive Canadian rights of the U.S. Food and Drug Administration approved drug Trulance (plecanatide) from Synergy Pharmaceuticals Inc. After the acquisition, Cipher Pharmaceuticals Inc. will develop, market, distribute, and sell Trulance (plecanatide) in the Canadian Market.

Asia Pacific peptide-based gastrointestinal disorders therapeutics market is expected to exhibit significant growth over the forecast period, owing to increasing investments made by players in the region to receive approval of novel peptide-based therapeutics. For instance, in 2014, Ironwood Pharmaceuticals, Inc. received US$ 15 million from Astellas Pharma Inc., a Japan-based pharmaceutical company, for initiating Phase III clinical trial of Linzess (linaclotide) in Japan, and receive its approval from Japanese Ministry of Health, Labor, and Welfare in 2016. Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. were under strategic partnership since 2009 for developing and commercializing linaclotide in Japan.

Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. Peptide-based gastrointestinal (GIT) disorders therapeutics are drugs that are used for the treatment of various GIT disorders such as short bowel syndrome, chronic constipation, and irritable bowel syndrome. In the recent past, some peptide-based therapeutics such as Trulance, Linaclotide, and Teduglutide received approval for the treatment of GIT disorders.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2028

Trulance is a guanylate cyclase-C agonist indicated for the treatment of chronic idiopathic constipation in adults. Linaclotide is a 14 amino acid peptide that acts as an agonist of guanylate cyclase C receptors in the intestine. It is a minimally absorbed agonist of guanylate cyclase C receptors in the intestine and is used for the treatment of chronic constipation and irritable bowel syndrome. Teduglutide is a new recombinant analogue for glucagon-like peptide (GLP) -2, a natural occurring peptide, which is secreted primarily by the lower gastrointestinal tract.

Peptide-Based Gastrointestinal Disorders Therapeutics Market Dynamics

Frequent approval and launch of novel peptide-based gastrointestinal disorders therapeutics in key regions is expected to drive the global peptide-based gastrointestinal disorders therapeutics market growth over the forecast period.

For instance, in 2017, Synergy Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA) approval for its new drug TRULANCE (plecanatide) 3 mg tablet. This drug is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

In 2012, Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. received the U.S. Food and Drug Administration approval for its drug called Linzess (linaclotide). Linzess (linaclotide) is a guanylate cyclase-C agonist used for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/peptide-based-gastrointestinal-disorders-therapeutics-market-2028

In 2016, Ironwood Pharmaceuticals, Inc.’s partner, Astellas Pharma Inc., received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for Linzess (linaclotide), and in 2017, Astellas Pharma Inc. launched Linzess (linaclotide) in Japan.

In 2012, NPS Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its drug Gattex (Teduglutide (rDNA origin)). Gattex 0.05 mg/kg/d injection is a new, recombinant analog of human glucagon-like peptide 2, a protein involved in the rehabilitation of the intestinal lining. It is indicated for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Sucg frequent approval is expected to cather peptide-based gastrointestinal disorders therapeutics market growth in near future.

Furthermore, increasing prevalence of gastrointestinal disorders is expected to rise the demand for peptide-based drugs, which will in turn drive the global peptide-based gastrointestinal disorders therapeutics market growth. For instance, according to the data published by the International Foundation for Functional Gastrointestinal Disorder in 2016, irritable bowel syndrome (IBS) is the most common functional gastrointestinal (GI) disorder and globally, around 10-15% of the population suffers from IBS.

Peptide-Based Gastrointestinal Disorders Therapeutics Market Key Players

Key players operating in the global peptide-based gastrointestinal disorders therapeutics market include Ironwood Pharmaceuticals, Inc., NPS Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Astellas Pharma Inc., Allergan plc., and Cipher Pharmaceuticals Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2028

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737

[expertofmarketinsights-blog]

Glucagon-Like Peptide-1 (Glp-1) Analogs Market To Register Unwavering Growth During in Global by 2026

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic medications. Also, GLP-1 analogs provide weight reduction benefit.

Get The PDF Brochure of This Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1252

High prevalence of diabetes in the U.S. and Asia-Pacific is expected to drive the growth of Glucagon-like peptide-1 analogs market

According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, around 425 million patients are suffering from diabetes worldwide. According to World Health Organization (WHO) report 2017, diabetes is one of top three cause of death among the non-communicable diseases. China (114.4 million), India (72.9 million) and U.S. (30.2 million) are top three economies having high prevalence of diabetes. Such high number of prevalence would offers an immense growth opportunity to the GLP-1 analogs market. This is also from the fact that approximately 212.4 million people worldwide are with undiagnosed diabetes. According to the International Diabetes Federation (IDF), the U.S. has highest prevalence of diabetes (13% of population), which is expected to drive the growth of glucagon-like peptide-1 analogs market, owing to cost effectiveness and high penetration of these product in market. GLP-1 analogs not only act in type-2 diabetes but also in type 1 diabetes with almost nil hypoglycemic effect, according to the study published in the Journal of American Health and Drug Benefit. According to study published in journal Obesity Review (2017), GLP-1 analogs aid in weight reduction of diabetic as well as non-diabetic obese patient. GLP-1 analog liraglutide is already approved in treating obese and overweight patient, which is expected to fuel the growth of the GLP-1 analogs market.

Increasing awareness amongst physicians regarding benefits of GLP-1 analogs over conventional anti-diabetic medication is propelling the growth of the market.

GLP-1 analogs are administered through subcutaneous injection with the help of injectable pen, which are relatively expensive (US$ 492 for 30-day therapy) as compared to conventional type-2 diabetes medication such as insulin sensitizers and secretagogues (US$ 5-9 for 30-day therapy) which is the major factor restraining growth of the market. Also, there is an issue of patient compliance. For instance, GLP-1 analogs need to be administered through injection as compared to other anti-diabetic medications, which are taken orally in tablet form.

Ask For Sample Copy of This Business Report : https://www.coherentmarketinsights.com/insight/request-sample/1252

Key players operating in the global Glucagon-like peptide-1 analogs market include Novo Nordisk, Eli-Lilly and Company, Sanofi, AstraZeneca plc, GlaxoSmithKline plc F., Hoffmann-La Roche Ltd.

Exenatide is the first GLP-1 analog approved in 2005, marketed by AstraZeneca under brand names Byetta and Byedureon Bcise. Its patent expired in October 2017. Teva got approval to commercialize the generic version of Byetta and its abbreviated new drug application is under FDA review. Novo Nordisk in October 2017 received FDA approval for once-a-week GLP-1 analog semaglutide. GSK announced to discontinue the global sale of albiglutide brand Tanzeum, Eperzan from July 2018 due to low profits. Taspoglutide is a molecule being developed by Roche targeting once a week dosing as against daily dosing regimen of other GLP-1 analogs. However, in 2016 it decided to halt clinical development due to high gastrointestinal side effects and hypersensitivity reactions.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

[kiransable07]

Antidiabetics Market Application And Regional Outlook And Segments Overview To 2026

According to a research report by Global Market Insights Inc., the global antidiabetics market would register a CAGR of 10.7% through the forecast timeframe. The market was valued at more than $65.5 billion in 2019. The increasing diabetic and obese population across the globe is slated to impel the antidiabetics market growth over the coming years. In addition, the growing geriatric population across the world, and their susceptibility to diabetes among other critical health issues would further complement the market outlook through 2026.

Geographically, the growing number of diabetes patients and the increasing geriatric population is expected to majorly fuel the Europe antidiabetics market outlook. In 2019, the region accounted for more than 32% of the overall industry share.

Request sample copy of this Report @ https://www.gminsights.com/request-sample/detail/504

In fact, as per the WHO (World Health Organization), approximately 422 million people globally suffer from diabetes and over 1.6 million deaths across the world are caused by diabetes related complications. Consequently, to facilitate better treatment options to reduce this high mortality rate, demand for antidiabetics is expected to increase tremendously.  

In addition, the integration of antidiabetics with technologically advanced diabetes treatment devices is expected to further fuel the industry share. Taking May 2019 for instance, Roche Diabetes Care launched its IDMS (Integrated Diabetes Management Solution) that comes with the “Accu-Chek Instant” blood glucose monitoring system and “mySugr” app. These solutions altogether make a next-generation blood glucose monitoring system.

In terms of product, the insulin segment accounted for the largest revenue share in the overall industry landscape in 2019 and is further slated to observe substantial business growth over the coming years. The projected growth can be ascribed to the rising number of patients diagnosed with type 2 diabetes.

In addition, the increasing adoption of numerous advanced treatments for better outcomes is likely to boost the preference for the product among consumers. Furthermore, increasing investments by market players in R&D of new products would also positively impel the segment share. Based on the aforementioned factors, the segment is projected to grow at a CAGR of more than 12.0% over the analysis period.

Browse key industry insights spread across 202 pages with 266 market data tables & 10 figures & charts from the report, “Antidiabetics Market Size By Product (Insulin {Rapid Acting, Long Acting, Premixed Insulin, Short Acting, Intermediate Acting}, Drug Class {Alpha-Glucosidase Inhibitors, Biguanides, Sulphonylureas, GLP-1 Agonist, Meglitinides, DPP-4 Inhibitors, SGLT-2, Thiazolidinedione}), By Patient Population (Pediatric, Adult, Geriatric), By Route of Administration (Insulin Syringe/Insulin Pen, Insulin Pump, Intravenous Infusion, Oral), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026” in detail along with the table of contents:

https://www.gminsights.com/industry-analysis/antidiabetics-market

With respect to patient population, the geriatric population represented approximately 40.0% of the industry share in 2019 and is slated to expand at a significant rate through the analysis period. As per the CDC (Centers for Disease Control and Prevention), over 25% of the U.S. population that is aged 65 years and above suffers from diabetes. Consequently, the growing diabetes cases among the geriatric population would greatly complement the segment share. Moreover, increasing government initiatives and awareness programs are also expected to positively impel the segment size.

With growing patient population, industry players are increasingly focusing on growth strategies like acquisitions, partnerships, investments, and new product launches to bring in more revenues. Taking September 2019 for instance, the U.S. FDA approved Rybelsus, an antidiabetic by Novo Nordisk to treat type 2 diabetes among adults. Rybelsus is the industry’s first GLP-1 (glucagon-like peptide-1) analog in a pill as well as new option for adults with type 2 diabetes.

The competitive landscape of the global antidiabetics market is inclusive of players such as Bristol-Myers Squibb, Boehringer Ingelheim, Bayer Corporation, and AstraZeneca among others.

Request for customization: @ https://www.gminsights.com/roc/504

About Global Market Insights:

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:

Arun Hegde

Corporate Sales, USA

Global Market Insights, Inc.

Phone:1-302-846-7766

Toll Free: 1-888-689-0688

Email: sales@gminsights.com    

Web: https://www.gminsights.com/        

[pharmaceuticalhealthcareana-blog]

Glucagon-Like Peptide-1 (Glp-1) Analogs Market - Global Industry Insights, 2017 – 2025

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic medications. Also, GLP-1 analogs provide weight reduction benefit.

Access Table of Content (TOC) Of the Report: https://www.coherentmarketinsights.com/ongoing-insight/toc/1252

[heathertruitt]

Grass fed butter benefits and side effects

Butter made from the milk of grass-fed cows offers more nutritional value than butter from grain-fed cows.

The same is true of beef; the dietary intake of animals is important in the same way that our own food choices are. To take the analogy of “You are what you eat” a step further, the quality of animal products depends on the quality of their nourishment and environment.

The animals our forebears raised and kept ate mostly grass throughout their lives. The nutritional composition of milk products in ages past, including cream, cheese and butter, reflected the cow’s diet.

Industrialized dairy products like those generally available in supermarkets today come mostly from cattle raised in Concentrated Animal Feeding Operations (CAFOs), where the focus is readying animals for production (dairy products) or slaughter (beef) as quickly and inexpensively as possible.

Calves owned by corporations in the dairy industry get milk when they’re young and move on to grass for a few months before being confined to CAFOs, where conditions are crowded and unsanitary. These animals are usually dosed with antibiotics to keep them from getting sick and hormones to speed growth.

Grains like corn and soybeans allow cattle to grow and fatten at faster rates than the grass they’re biologically suited to consume, so they mature in less than a quarter of the time it took 75 years ago, when diets consisted mainly of grass. (1)

The demand for grass-fed dairy products and beef continues to grow. Comparing the nutritional values of grass-fed butter with commercial butter will give you an idea why.

If you’re interested in finding out whether grass-fed butter is superior, you probably already know butter isn’t the killer it’s been made out to be. The myth about saturated fats causing heart disease and other health disorders dissipates as current research data accumulates. (2, 3)

Turns out the real “fat” villains are trans fats, rather than saturated fats like those found in butter. (4)

Cattle’s ruminant digestive system with four-compartment stomachs is uniquely suited to converting the cellulose in grass to protein and fat, a feat humans can’t manage. (5) The goodies from all that grass end up in dairy products and beef.

When cattle are raised, fattened and maintained on grains, nutrients extracted from feed will be found in the butter, cream, cheese, and milk from those animals, as well as the muscle tissue, or meat.

Benefits

Grass-fed butter is a rich source of conjugated linoleic acid (CLA) (6), a fatty acid useful in accelerating fat loss. CLA has also been shown to have positive effects on patients suffering from cardiovascular disease, cancer, chronic inflammation, and diminished immune response. (7)

If you’re looking to trim down and add muscle, CLA matters; higher levels of the fatty acid work to decrease body fat while increasing lean body mass. (8)

The amount and quality of the vitamin K2 found in butter matters, too. Vitamin K2 is crucial because it de-calcifies the arteries and keeps them clear. (9, 10) Adequate intake of vitamin K2 helps prevent calcium from leaching out of the bones and depositing in the arteries, decreasing the risk of developing osteoporosis. (11, 12)

One study found that for every 10 micrograms of vitamin k2 they consumed, participants’ risk of developing heart disease dropped by 9%. (13)

Another European trial determined subjects with the highest vitamin K2 intake decreased their risk of heart disease by 57%. (14)

Butter from grass-fed cows is among the richest sources of vitamin K2, along with natto (a fermented soy product), goose liver and egg yolks. (15)

For many years medical professionals have marked high cholesterol as the most reliable predictor for developing heart disease, but now chronic inflammation looks like the forerunner. (16, 17)  There can be many causes of chronic inflammation (18), some of which can be moderated by nutritional strategies like following an anti-inflammatory diet.

Reduction of existing inflammation can help cut your risk for a host of health concerns, including arthritis, inflammatory bowel diseases, obesity, heart disease, anxiety disorders, diabetes and osteoporosis. Grass-fed butter is loaded with butyrate, a fatty acid with anti-inflammatory properties. (19)

Ongoing research may help scientists understand exactly how this works, but studies suggest that bacteria in the gut digest fiber and turn it into butyrate. (20, 21)

We’ve already touched on the benefits of  CLA, vitamin K2 and butyrate found in abundant quantities in grass-fed butter, all of which help protect against heart disease and other serious health disorders.

Grass-fed butter is also rich in omega-3 fatty acids, which help cultivate good cardiovascular health and have other positive effects on overall health and wellness. Cold water fish supplies many populations with adequate levels of omega-3 fatty acids, but if you don’t live in a place where fresh fish is readily available, grass-fed butter may be your best reliable source of omega-3 fatty acids. (22)

The number of cattle in America raised on grass is small compared to other parts of the world like Australia, where grass-fed butter is the norm. One Australian study showed participants who ate the most high-fat dairy products like butter, cream and cheese enjoyed a 69% lower risk of death from cardiovascular disease than those who ate the least. (23)

In a number of European countries where cattle are traditionally raised and maintained on pasture, the consumption of high-fat dairy products is associated with lower risk for heart disease. (24, 25)

Margarine made with trans fats has been linked to higher rates of coronary heart disease in men (26), so if you eat real butter, you made the right choice.

Take yourself another step up the ladder of better nutrition: treat yourself to grass-fed butter and cut your risk of developing heart disease and a respectable list of other modern disorders. Remember, the cardiovascular disease epidemic is recent, butter has been around forever.

Side effects

Some people experience lactose intolerence (inability to digest lactose, which is the sugar found in dairy) with heavy dosages in butter

Recap

Grass is the natural nourishment for cattle. If you’re going to eat butter, it’s worth the extra money to get grass-fed butter.

https://bodynutrition.org/grass-fed-butter/

https://bodynutritionorg.wordpress.com/2017/12/09/grass-fed-butter-benefits-and-side-effects/